Virpax Pharmaceuticals, Inc.
General ticker "VRPX" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $1.4M (TTM average)
Virpax Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -10.5%.
Estimated limits based on current volatility of 0.1%: low 0.02$, high 0.02$
Factors to consider:
- Total employees count: 2 (-71.4%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Insufficient funding, Clinical trial failures, Labor/talent shortage/retention, Market acceptance, Market competition
- Earnings for 15 months up through Q1 (+1 year) are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [17.35$, 101.75$]
- 2024-12-30 to 2025-12-30 estimated range: [5.42$, 33.58$]
Financial Metrics affecting the VRPX estimates:
- Negative: with PPE of -0.4 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -9.78 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
Short-term VRPX quotes
Long-term VRPX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $12.03MM | $21.85MM | $15.69MM |
| Operating Income | $-12.03MM | $-21.85MM | $-15.69MM |
| Non-Operating Income | $-0.03MM | $0.19MM | $0.50MM |
| Interest Expense | $0.09MM | $0.00MM | $0.00MM |
| R&D Expense | $4.84MM | $10.76MM | $5.12MM |
| Income(Loss) | $-12.06MM | $-21.65MM | $-15.19MM |
| Profit(Loss)* | $-12.15MM | $-21.46MM | $-15.19MM |
| Stockholders Equity | $37.48MM | $16.58MM | $1.93MM |
| Assets | $39.57MM | $19.67MM | $9.63MM |
| Operating Cash Flow | $-14.54MM | $-17.85MM | $-9.85MM |
| Financing Cash Flow | $51.33MM | $0.00MM | $0.00MM |
| Earnings Per Share** | $-10.37 | $-18.32 | $-12.97 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.